IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 39.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 918 shares of the company’s stock after buying an additional 262 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in IDEXX Laboratories were worth $379,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FSA Wealth Management LLC acquired a new position in IDEXX Laboratories in the third quarter valued at approximately $25,000. Ashton Thomas Securities LLC purchased a new stake in IDEXX Laboratories in the third quarter valued at approximately $37,000. Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $31,000. Kestra Investment Management LLC purchased a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $38,000. Finally, Crews Bank & Trust purchased a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $41,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Down 1.0 %

NASDAQ:IDXX opened at $437.23 on Thursday. The stock has a fifty day moving average price of $436.83 and a two-hundred day moving average price of $450.33. The stock has a market capitalization of $35.56 billion, a price-to-earnings ratio of 40.98, a PEG ratio of 3.41 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $574.94.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on IDXX shares. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. Barclays boosted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Morgan Stanley cut their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Finally, Piper Sandler upped their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.